{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T16:03:44Z","timestamp":1766678624438},"reference-count":32,"publisher":"The Journal of Rheumatology","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:p>Dactylitis, a hallmark clinical feature of psoriatic arthritis (PsA) and other spondyloarthropathies, may also be a severity marker for PsA and psoriasis. Traditionally, clinicians have used nonsteroidal antiinflammatory drugs and local corticosteroid injections to treat dactylitis, although conventional disease-modifying antirheumatic drugs are also used. We performed a systematic literature review to determine the most efficacious current treatment options for dactylitis in PsA. Effect sizes were greatest for the biologic agents ustekinumab, certolizumab, and infliximab, suggesting that therapy with one of these agents should be initiated in patients with dactylitis. However, the limited data highlight the need for randomized, placebo-controlled trials, with dactylitis as a primary outcome, to determine a valid, reliable, and responsive clinical outcome measure for PsA patients with dactylitis.<\/jats:p>","DOI":"10.3899\/jrheum.140879","type":"journal-article","created":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T11:18:15Z","timestamp":1414840695000},"page":"2295-2300","source":"Crossref","is-referenced-by-count":44,"title":["Comprehensive Treatment of Dactylitis in Psoriatic Arthritis"],"prefix":"10.3899","volume":"41","author":[{"given":"Shawn","family":"Rose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Toloza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson","family":"Bautista-Molano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip S.","family":"Helliwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2014,11,1]]},"reference":[{"key":"2018112909335632000_41.11.2295.1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(73)90035-8"},{"key":"2018112909335632000_41.11.2295.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130643"},{"key":"2018112909335632000_41.11.2295.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205056"},{"key":"2018112909335632000_41.11.2295.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"2018112909335632000_41.11.2295.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"2018112909335632000_41.11.2295.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"2018112909335632000_41.11.2295.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130163"},{"key":"2018112909335632000_41.11.2295.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.34436"},{"key":"2018112909335632000_41.11.2295.9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120254"},{"key":"2018112909335632000_41.11.2295.10","first-page":"201","article-title":"Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: A long-term follow-up study","volume":"6","author":"Cantini","year":"2012","journal-title":"Biologics"},{"key":"2018112909335632000_41.11.2295.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.152223"},{"key":"2018112909335632000_41.11.2295.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.07.004"},{"key":"2018112909335632000_41.11.2295.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110242"},{"key":"2018112909335632000_41.11.2295.14","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1504-5"},{"key":"2018112909335632000_41.11.2295.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100069"},{"key":"2018112909335632000_41.11.2295.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c147"},{"key":"2018112909335632000_41.11.2295.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"2018112909335632000_41.11.2295.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60140-9"},{"key":"2018112909335632000_41.11.2295.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092767"},{"key":"2018112909335632000_41.11.2295.20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem315"},{"key":"2018112909335632000_41.11.2295.21","first-page":"869","article-title":"Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: Findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"35","author":"Antoni","year":"2008","journal-title":"J Rheumatol"},{"key":"2018112909335632000_41.11.2295.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058339"},{"key":"2018112909335632000_41.11.2295.23","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909335632000_41.11.2295.24","first-page":"1302","article-title":"Measuring dactylitis in clinical trials: Which is the best instrument to use?","volume":"34","author":"Healy","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909335632000_41.11.2295.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"2018112909335632000_41.11.2295.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"2018112909335632000_41.11.2295.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"2018112909335632000_41.11.2295.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.20253"},{"key":"2018112909335632000_41.11.2295.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.11201"},{"key":"2018112909335632000_41.11.2295.30","first-page":"2274","article-title":"A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis","volume":"28","author":"Salvarani","year":"2001","journal-title":"J Rheumatol"},{"key":"2018112909335632000_41.11.2295.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780391210"},{"key":"2018112909335632000_41.11.2295.32","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130461"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.140879","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T18:42:38Z","timestamp":1543516958000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.140879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,11,1]]},"published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.3899\/jrheum.140879"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.140879","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}